



Gesundheit Österreich
GmbH



More transparency of pharmaceutical prices: *The EURIPID project*

STAMP meeting
08. 12. 2017 Brussels
Gergely Németh
(project manager)

Disclaimer

“The content of this presentation represents the views of the author only and is his/her sole responsibility; it can not be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.”

Content

1. Introduction

2. SWOT and challenges

3. Access

4. Facing the future


1.1 What is the EURIPID undertaking?

A voluntary non-profit **COLLABORATION** of the European P&R authorities for the mutual sharing of price information of medicinal products

A **TECHNICAL TOOL** to make prices of pharmaceuticals more transparent in Europe

An attempt to create a comprehensive, continuously maintained, easy-to-use online **DATABASE** of prices of reimbursed pharmaceuticals

1.2 History



1.3 The EURIPID Collaboration

Legal issues

- Framework Partnership Agreement
- General Terms and Conditions
- Terms and Conditions of Use of the Website

Organisation

- Founders, Partners, Associated Partners, European Commission
- Board of Participants (BoP) (one delegate per country + EC)
- Executive Committee (3 delegates of the BoP + OEP + GÖG/ÖBIG + EC repr.)
- project team (OEP & GÖG/ÖBIG)


Finances

- non-profit
- annual contribution fee equally shared
- the budget depends on the number of participants

1.4 Status of recruitment

Participating countries in 2017:

Austria	Italy
Belgium	Latvia
Bulgaria	Lithuania
Croatia	Netherlands
Czech Republic	Norway
Cyprus	Poland
Denmark	Portugal
Estonia	Slovakia
Finland	Slovenia
France	Spain
Greece	Sweden
Hungary	Switzerland
Ireland	United Kingdom
Israel	




Not participants but data available: Iceland

Former participant: Albania, Romania

1.5 Operational model



1.6 Information content



* Converted to another currency

2.1 SWOT analysis of the EURIPID Collaboration

8 years of experience
Successful operational model
Most EU Member States are participants

Limited in scope
Only official prices
Access is restricted

Bringing together the experts on pricing
Extension of the dataset
Cooperation with other databases/projects (e.g. EMVS)
Geographic extension of the collaboration

Confidential pricing

2.2 European Parliament INI Report

Report – EU options for improving access medicines – A8-0040/2017 – Committee on the Environment, Public Health and Food Safety

36. Notes that the EURIPID project needs more transparency from Members States to include the real prices paid by them;

<http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&reference=A8-2017-0040&format=XML&language=EN>

2.3 Reply of EURIPID to the call of the EP

Limited and step-wise increase of transparency within the EU

Voluntary cooperation between the Member States and pharma companies

No price distortion mechanisms for the concerned products in any MS

The principles of ERP and price differentiation (if any) shall be laid down

EURIPID could be of large value in such a procedure

3.1 Reasons of access restrictions

The Board of Participants has the right to decide about the access policy

Preventing free riding

Data ownership issues

Concerns about parallel trade

Concerns about the misinterpretation of **prices** (sales volumes, pricing structures matters, real prices vs. list prices)

Incalculable effect on pricing and access to medicines on a global level

The stakeholders have not yet expressed their explicit interest for accessing the EURIPID website

4.1 DG SANTE grant objectives

to achieve a better coordination at the EU level in order to facilitate the control by the Member States of public budgets for medicinal products whilst avoiding/mitigating possible negative impacts on patient access to medicinal care.

SO.1

Determining an optimised dataset and data lay-out

(in collaboration with the stakeholders)

SO.2

Providing the necessary (additional) information

SO.3

Developing a Guidance Document on external reference pricing

(in collaboration with the stakeholders)

4.2 Facing the future

Development of the EURIPID website (under the EU grant):

- Information on the existence of managed entry agreements
- Information on sales volumes

Development of a technical Guidance Document on external reference pricing (under the EU grant)

Cooperation with other initiatives:

- EMA article 57 database
- EMVS (European Medicines Verification System)
- EUROSTAT

Post-grant period

- Implementation of the recommendations of the Guidance Document
- Training of users



THANKS FOR YOUR ATTENTION!

nemeth.ger@neak.gov.hu